| General information |
| Database: | DB00783 |
| Objective: | Single agent chemotherapy is standard for second and third line treatment of non small cell lung cancer (non small cell lung cancer). Combination therapy to date has not proven to be superior to single agents in this setting, often adding toxicity without any additional efficacy. they investigated the activity and tolerability of the combination of oxaliplatin, pemetrexed, and bevacizumab in patients with previously treated advanced non small cell lung cancer. |
| Authors: | Heist RS, et al |
| Title: | a phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non small cell lung cancer. |
| Journal: | J Thorac Oncol. |
| Year: | 2008 |
| PMID: | 18827612 |
| Trial Design |
| Clinical Trial Id: | NA |
| Agent: | bevacizumab
|
| Target: | Vascular endothelial growth factor
|
| Cancer Type: | non small cell lung cancer |
| Cancer Subtype: | advanced non small cell lung cancer |
| Therapy Type: | com |
| Therapeutic Combination Type: | 2 |
| Therapeutic Combination Content: | oxaliplatin, pemetrexed, + bevacizumab |
| Study Type: | A multicenterphase II trial |
| Key Patients Feature: | Eligibility criteria included performance status 0 to 1, nonsquamous histology, and at least one prior chemotherapy regimen. Patients with treated brain metastases were allowed. |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | this trial evaluated the safety and efficacy of the combination of pemetrexed (500 mg/m), oxaliplatin (120 mg/m), and bevacizumab (15 mg/kg), given every 21 days, in patients with previously treated advanced non small cell lung cancer. |
| Primary End Point: | response rate |
| Secondary End Point: | progression free survival and overall survival. |
| Patients Number: | 66 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | 27% |
| Disease Control Rate: | 71% |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | 5.8 months (95% confidence interval 4.17.8 months) |
| Median OS A vs. C: | 12.5 months (95% confidence interval 7.317 months) |
| Adverse Event(agent arm): | NA |
| Conclusions: | Treatment with oxaliplatin and pemetrexed in combination with the targeted antiangiogenic agent bevacizumab yielded promising efficacy with manageable toxicity in the previously treated advanced non small cell lung cancer population. |